journal article·2019-12-04Open access

Clinicopathological and prognostic value of LINC01296 in cancers: a meta-analysis

Wei Feng, Cui Zhai, Wenhua Shi, Qianqian Zhang, Xin Yan, Jian Wang, Qingting Wang, Manxiang Li

Abstract

Objective: The long intergenic non-coding RNA 01296 (LINC01296) has been reported to be overexpressed in multiple tumours. However, the role of LINC01296 in clinicopathologic and prognostic value in cancers remains completely unknown. The aim of the present meta-analysis was to comprehensively elucidate the correlation between LINC01296 with clinicopathological features and survival outcomes in tumours.Methods: Electronic databases of PubMed, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wanfang Database were used to search relevant studies. The role of LINC01296 in cancers was evaluated by pooled hazard ratios (HRs), odds ratios (ORs) and 95% confidence intervals (CIs).Results: In total, nine studies compromising 720 participants were enrolled in this analysis. The pooled results showed increased LINC01296 expression could predict unfavourable overall survival (OS) (HR = 1.89, 95%CI = 1.47–2.43, p < .001). Additionally, elevated LINC01296 expression was correlated with clinical stage (OR = 2.95, 95%CI = 2.13–4.08, p < .001), lymph node metastasis (OR = 2.76, 95%CI = 2.00–3.81, p < .001), tumour size (OR = 2.80, 95%CI = 1.77–4.41, p < .001), and tumour differentiation (OR = 2.11, 95%CI = 1.36–3.27, p < .001) in patients with cancers.Conclusion: The results of this meta-analysis indicated LINC01296 was a novel biomarker for prognosis and clinicopathological parameters in cancers.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cancer-related molecular mechanisms research · RNA modifications and cancer · Circular RNAs in diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Xi’an Jiaotong University

Funding

National Natural Science Foundation of China

References (27)

Show source-provided references
1. 10.3322/caac.2149210.3322/caac.21492 ↗
2. 10.21873/cgp.2002710.21873/cgp.20027 ↗
3. 10.3389/fgene.2015.0014510.3389/fgene.2015.00145 ↗
4. 10.1016/j.gene.2018.07.00410.1016/j.gene.2018.07.004 ↗
5. 10.1186/s13046-018-0994-x10.1186/s13046-018-0994-x ↗
6. 10.1002/jcp.2791810.1002/jcp.27918 ↗
7. 10.1111/cpr.1251910.1111/cpr.12519 ↗
8. 10.7150/jca.2726310.7150/jca.27263 ↗
9. 10.1002/jcp.2796210.1002/jcp.27962 ↗
10. 10.2147/CMAR.S16137310.2147/CMAR.S161373 ↗
11. 10.1038/s41598-017-00327-010.1038/s41598-017-00327-0 ↗
12. Wang L, Meng D, Wang Y, et al. Long non-coding RNA LINC01296 promotes esophageal squamous cell carcinoma cell proliferation and invasion by epigenetic suppression of KLF2. Am J Cancer Res. 2018;8:2020–2029.
13. 10.1016/j.biopha.2017.10.06610.1016/j.biopha.2017.10.066 ↗
14. 10.1007/s13277-015-3448-510.1007/s13277-015-3448-5 ↗
15. 10.1002/jcp.2723510.1002/jcp.27235 ↗
16. 10.2147/OTT.S19280910.2147/OTT.S192809 ↗
17. 10.2147/OTT.S12992810.2147/OTT.S129928 ↗
18. 10.1186/1745-6215-8-1610.1186/1745-6215-8-16 ↗
19. 10.1016/j.cca.2018.05.01010.1016/j.cca.2018.05.010 ↗
20. 10.1002/jcb.2741110.1002/jcb.27411 ↗
21. Zhang D, Li H, Xie J, et al. Long noncoding RNA LINC01296 promotes tumour growth and progression by sponging miR-5095 in human cholangiocarcinoma. Int J Oncol. 2018;52:1777–1786.
22. Wang B, Liang T, Li J. Long noncoding RNA LINC01296 is associated with poor prognosis in ESCC and promotes ESCC cell proliferation, migration and invasion. Eur Rev Med Pharmacol Sci. 2018;22:4524–4531.
23. 10.1186/s40659-017-0136-510.1186/s40659-017-0136-5 ↗
24. 10.2147/CMAR.S18252110.2147/CMAR.S182521 ↗
25. Wang L, Chunyan Q, Zhou Y, et al. BCAR4 increase cisplatin resistance and predicted poor survival in gastric cancer patients. Eur Rev Med Pharmacol Sci. 2017;21:4064–4070.
26. 10.18632/oncotarget.1635810.18632/oncotarget.16358 ↗
27. Yu X, Pang L, Yang T, et al. lncRNA LINC01296 regulates the proliferation, metastasis and cell cycle of osteosarcoma through cyclin D1. Oncol Rep. 2018;40:2507–2514.